Novartis Ag Adr Stock Filter Stocks by Fundamentals
NVS Stock | USD 96.73 0.85 0.89% |
Novartis AG ADR fundamentals help investors to digest information that contributes to Novartis' financial success or failures. It also enables traders to predict the movement of Novartis Stock. The fundamental analysis module provides a way to measure Novartis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novartis stock.
Novartis | Shares Owned by Insiders |
Novartis Institutional Holders
Institutional Holdings refers to the ownership stake in Novartis that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Novartis' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Novartis' value.Shares | Principal Financial Group Inc | 2023-12-31 | 2.5 M | Northern Trust Corp | 2023-12-31 | 2.1 M | Envestnet Asset Management Inc | 2023-12-31 | 2 M | Wells Fargo & Co | 2023-12-31 | 2 M | Blackrock Inc | 2023-12-31 | 1.8 M | State Street Corporation | 2023-12-31 | 1.8 M | Ubs Group Ag | 2023-12-31 | 1.7 M | Cullen Capital Management, Llc | 2023-12-31 | 1.6 M | Grantham, Mayo, Van Otterloo & Co., Llc | 2023-12-31 | 1.5 M | Dodge & Cox | 2023-12-31 | 13.2 M | Primecap Management Company | 2023-12-31 | 12.9 M |
Novartis Fundamentals
Return On Equity | 0.16 | ||||
Return On Asset | 0.0727 | ||||
Profit Margin | 0.32 % | ||||
Operating Margin | 0.25 % | ||||
Current Valuation | 208.38 B | ||||
Shares Outstanding | 2.04 B | ||||
Shares Owned By Institutions | 6.93 % | ||||
Number Of Shares Shorted | 4.53 M | ||||
Price To Earning | 9.22 X | ||||
Price To Book | 4.20 X | ||||
Price To Sales | 4.25 X | ||||
Revenue | 46.66 B | ||||
Gross Profit | 36.74 B | ||||
EBITDA | 18.47 B | ||||
Net Income | 8.57 B | ||||
Cash And Equivalents | 4.64 B | ||||
Cash Per Share | 8.84 X | ||||
Total Debt | 26.35 B | ||||
Debt To Equity | 0.47 % | ||||
Current Ratio | 1.31 X | ||||
Book Value Per Share | 22.83 X | ||||
Cash Flow From Operations | 14.46 B | ||||
Short Ratio | 2.77 X | ||||
Earnings Per Share | 4.10 X | ||||
Price To Earnings To Growth | 5.22 X | ||||
Target Price | 113.01 | ||||
Number Of Employees | 76.06 K | ||||
Beta | 0.46 | ||||
Market Capitalization | 198.19 B | ||||
Total Asset | 99.94 B | ||||
Retained Earnings | 49.65 B | ||||
Working Capital | 4.09 B | ||||
Current Asset | 22.84 B | ||||
Current Liabilities | 23.71 B | ||||
Z Score | 6.33 | ||||
Annual Yield | 0.04 % | ||||
Five Year Return | 3.53 % | ||||
Net Asset | 99.94 B | ||||
Last Dividend Paid | 3.92 |
About Novartis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 108000 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Novartis Piotroski F Score and Novartis Altman Z Score analysis. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Novartis Stock analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
CEOs Directory Screen CEOs from public companies around the world | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 4.987 | Dividend Share 3.919 | Earnings Share 4.1 | Revenue Per Share 22.467 | Quarterly Revenue Growth 0.074 |
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.